Benzimidazolone carboxylic acid derivatives

• US 7,595,329 B2
• Filed: 06/14/2005
• Issued: 09/29/2009
• Est. Priority Date: 06/15/2004
• Status: Expired due to Fees

• Current Assignee: Pfizer Inc.
• Original Assignee: Pfizer Inc.
• Inventors: Ando, Koji, Numata, Toyoharu, Uchida, Chikara, Sone, Hiroki, Iguchi, Satoru, Murata, Yoshinori, Ueki, Tatsuo, Murase, Noriaki
• Primary Examiner(s): Shameem; Golam M
• Application Number:
  US11/153,757
• Publication Number:
  US 20050277671A1
• Time in Patent Office: 1,568 Days
• Field of Search: 546/268.1, 546/272.7, 546/273.4, 546/273.7, 546/184, 546/192, 546/196, 546/197, 546/199, 548/300.1, 548/301.7, 548/302.7, 548/304.4, 548/304.7, 548/306.1, 514/315, 514/317, 514/320, 514/322, 514/385, 514/387, 514/321
• US Class Current: 514/322
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/06 Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• CPC Class Codes: A61P 1/10 Laxatives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: C07D 211/26 with hydrocarbon radicals, substituted by nitrogen atoms
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 405/14 containing three or more hetero rings

Abstract

This invention relates to compounds of the formula (I):

wherein R¹, R², R³, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT₄ receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer'"'"'s disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

Claims

1. The compound 1-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid or a pharmaceutically aceptable salt thereof.

2. A method of treating gastroesophageal reflux disease (GERD) in a mammal, including a human, comprising administering to the mammal a therapeutically effective amount of the compound or pharmaceutically acceptable salt of claim 1.

3. A pharmaceutical composition comprising the compound 1-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid or a pharmaceutically acceptable salt or solvate thereof, with or without at least one pharmaceutically acceptable carrier.

4. A method of treating gastroesophageal reflux disease (GERD) in a mammal, including a human, comprising administering to the mammal a therapeutically effective a amount of the composition of claim 3.